{"downloaded": true, "htmlmade": false, "full": {"id": "30093449", "source": "MED", "pmid": "30093449", "pmcid": "PMC6295246", "fullTextIdList": {"fullTextId": "PMC6295246"}, "doi": "10.1158/1078-0432.ccr-18-1381", "title": "Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma.", "authorString": "DuBois SG, Mosse YP, Fox E, Kudgus RA, Reid JM, McGovern R, Groshen S, Bagatell R, Maris JM, Twist CJ, Goldsmith K, Granger MM, Weiss B, Park JR, Macy ME, Cohn SL, Yanik G, Wagner LM, Hawkins R, Courtier J, Lai H, Goodarzian F, Shimada H, Boucher N, Czarnecki S, Luo C, Tsao-Wei D, Matthay KK, Marachelian A.", "authorList": {"author": [{"fullName": "DuBois SG", "firstName": "Steven G", "lastName": "DuBois", "initials": "SG", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, Massachusetts. steven_dubois@dfci.harvard.edu."}}}, {"fullName": "Mosse YP", "firstName": "Yael P", "lastName": "Mosse", "initials": "YP", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Pediatrics, Children's Hospital of Philadelphia and University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."}}}, {"fullName": "Fox E", "firstName": "Elizabeth", "lastName": "Fox", "initials": "E", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Pediatrics, Children's Hospital of Philadelphia and University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."}}}, {"fullName": "Kudgus RA", "firstName": "Rachel A", "lastName": "Kudgus", "initials": "RA", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Pharmacology, Mayo Clinic, Rochester, Minnesota."}}}, {"fullName": "Reid JM", "firstName": "Joel M", "lastName": "Reid", "initials": "JM", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Pharmacology, Mayo Clinic, Rochester, Minnesota."}}}, {"fullName": "McGovern R", "firstName": "Renee", "lastName": "McGovern", "initials": "R", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Pharmacology, Mayo Clinic, Rochester, Minnesota."}}}, {"fullName": "Groshen S", "firstName": "Susan", "lastName": "Groshen", "initials": "S", "authorId": {"@type": "ORCID", "#text": "0000-0001-9705-1012"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Preventive Medicine, USC Keck School of Medicine and Children's Hospital Los Angeles, Los Angeles, California."}}}, {"fullName": "Bagatell R", "firstName": "Rochelle", "lastName": "Bagatell", "initials": "R", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Pediatrics, Children's Hospital of Philadelphia and University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."}}}, {"fullName": "Maris JM", "firstName": "John M", "lastName": "Maris", "initials": "JM", "authorId": {"@type": "ORCID", "#text": "0000-0002-8088-7929"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Pediatrics, Children's Hospital of Philadelphia and University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."}}}, {"fullName": "Twist CJ", "firstName": "Clare J", "lastName": "Twist", "initials": "CJ", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Pediatrics, Roswell Park Cancer Institute, Buffalo, New York."}}}, {"fullName": "Goldsmith K", "firstName": "Kelly", "lastName": "Goldsmith", "initials": "K", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Pediatrics, Children's Healthcare of Atlanta and Emory University, Atlanta, Georgia."}}}, {"fullName": "Granger MM", "firstName": "M Meaghan", "lastName": "Granger", "initials": "MM", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Pediatrics, Cook Children's Hospital, Fort Worth, Texas."}}}, {"fullName": "Weiss B", "firstName": "Brian", "lastName": "Weiss", "initials": "B", "authorId": {"@type": "ORCID", "#text": "0000-0001-5154-3134"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Pediatrics, Cincinnati Children's Medical Center, Cincinnati, Ohio."}}}, {"fullName": "Park JR", "firstName": "Julie R", "lastName": "Park", "initials": "JR", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Pediatrics, Seattle Children's Hospital and University of Washington, Seattle, Washington."}}}, {"fullName": "Macy ME", "firstName": "Margaret E", "lastName": "Macy", "initials": "ME", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Pediatrics, Children's Hospital Colorado and University of Colorado, Aurora, Colorado."}}}, {"fullName": "Cohn SL", "firstName": "Susan L", "lastName": "Cohn", "initials": "SL", "authorId": {"@type": "ORCID", "#text": "0000-0001-5749-7650"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Pediatrics, Comer Children's Hospital and University of Chicago, Chicago, Illinois."}}}, {"fullName": "Yanik G", "firstName": "Greg", "lastName": "Yanik", "initials": "G", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Pediatrics, CS Mott Children's Hospital and University of Michigan, Ann Arbor, Michigan."}}}, {"fullName": "Wagner LM", "firstName": "Lars M", "lastName": "Wagner", "initials": "LM", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Pediatrics, University of Kentucky College of Medicine, Lexington, Kentucky."}}}, {"fullName": "Hawkins R", "firstName": "Randall", "lastName": "Hawkins", "initials": "R", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Radiology, UCSF Benioff Children's Hospital and UCSF School of Medicine, San Francisco, California."}}}, {"fullName": "Courtier J", "firstName": "Jesse", "lastName": "Courtier", "initials": "J", "authorId": {"@type": "ORCID", "#text": "0000-0003-2717-8653"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Radiology, UCSF Benioff Children's Hospital and UCSF School of Medicine, San Francisco, California."}}}, {"fullName": "Lai H", "firstName": "Hollie", "lastName": "Lai", "initials": "H", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Radiology, USC Keck School of Medicine and Children's Hospital Los Angeles, Los Angeles, California."}}}, {"fullName": "Goodarzian F", "firstName": "Fariba", "lastName": "Goodarzian", "initials": "F", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Radiology, USC Keck School of Medicine and Children's Hospital Los Angeles, Los Angeles, California."}}}, {"fullName": "Shimada H", "firstName": "Hiroyuki", "lastName": "Shimada", "initials": "H", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Pathology, USC Keck School of Medicine and Children's Hospital Los Angeles, Los Angeles, California."}}}, {"fullName": "Boucher N", "firstName": "Najee", "lastName": "Boucher", "initials": "N", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Pediatrics, USC Keck School of Medicine and Children's Hospital Los Angeles, Los Angeles, California."}}}, {"fullName": "Czarnecki S", "firstName": "Scarlett", "lastName": "Czarnecki", "initials": "S", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Pediatrics, USC Keck School of Medicine and Children's Hospital Los Angeles, Los Angeles, California."}}}, {"fullName": "Luo C", "firstName": "Chunqiao", "lastName": "Luo", "initials": "C", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Preventive Medicine, USC Keck School of Medicine and Children's Hospital Los Angeles, Los Angeles, California."}}}, {"fullName": "Tsao-Wei D", "firstName": "Denice", "lastName": "Tsao-Wei", "initials": "D", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Preventive Medicine, USC Keck School of Medicine and Children's Hospital Los Angeles, Los Angeles, California."}}}, {"fullName": "Matthay KK", "firstName": "Katherine K", "lastName": "Matthay", "initials": "KK", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Pediatrics, UCSF Benioff Children's Hospital and UCSF School of Medicine, San Francisco, California."}}}, {"fullName": "Marachelian A", "firstName": "Araz", "lastName": "Marachelian", "initials": "A", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Pediatrics, USC Keck School of Medicine and Children's Hospital Los Angeles, Los Angeles, California."}}}]}, "authorIdList": {"authorId": [{"@type": "ORCID", "#text": "0000-0001-5154-3134"}, {"@type": "ORCID", "#text": "0000-0001-5749-7650"}, {"@type": "ORCID", "#text": "0000-0001-9705-1012"}, {"@type": "ORCID", "#text": "0000-0002-8088-7929"}, {"@type": "ORCID", "#text": "0000-0003-2717-8653"}]}, "dataLinksTagsList": {"dataLinkstag": ["supporting_data", "altmetrics"]}, "journalInfo": {"issue": "24", "volume": "24", "journalIssueId": "2761195", "dateOfPublication": "2018 Dec", "monthOfPublication": "12", "yearOfPublication": "2018", "printPublicationDate": "2018-12-01", "journal": {"title": "Clinical cancer research : an official journal of the American Association for Cancer Research", "ISOAbbreviation": "Clin Cancer Res", "medlineAbbreviation": "Clin Cancer Res", "NLMid": "9502500", "ISSN": "1078-0432", "ESSN": "1557-3265"}}, "pubYear": "2018", "pageInfo": "6142-6149", "abstractText": "<h4>Purpose</h4>In phase I testing, alisertib tablets with irinotecan and temozolomide showed significant antitumor activity in patients with neuroblastoma. This study sought to confirm activity of this regimen; evaluate an alisertib oral solution; and evaluate biomarkers of clinical outcomes.<h4>Patients and methods</h4>We conducted a two-stage phase II trial of alisertib tablets (60 mg/m<sup>2</sup>/dose \u00d7 7 days), irinotecan (50 mg/m<sup>2</sup>/dose i.v. \u00d7 5 days), and temozolomide (100 mg/m<sup>2</sup>/dose orally \u00d7 5 days) in patients with relapsed or refractory neuroblastoma. The primary endpoint was best objective response. A separate cohort was treated with alisertib at 45 mg/m<sup>2</sup> using oral solution instead of tablets. Exploratory analyses sought to identify predictors of toxicity, response, and progression-free survival (PFS) using pooled data from phase I, phase II, and oral solution cohorts.<h4>Results</h4>Twenty and 12 eligible patients were treated in the phase II and oral solution cohorts, respectively. Hematologic toxicities were the most common adverse events. In phase II, partial responses were observed in 19 evaluable patients (21%). The estimated PFS at 1 year was 34%. In the oral solution cohort, 3 patients (25%) had first cycle dose-limiting toxicity (DLT). Alisertib oral solution at 45 mg/m<sup>2</sup> had significantly higher median <i>C</i> <sub>max</sub> and exposure compared with tablets at 60 mg/m<sup>2</sup>. Higher alisertib trough concentration was associated with first cycle DLT, whereas <i>MYCN</i> amplification was associated with inferior PFS.<h4>Conclusions</h4>This combination shows antitumor activity, particularly in patients with <i>MYCN</i> nonamplified tumors. Data on an alisertib oral solution expand the population able to be treated with this agent.", "affiliation": "Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, Massachusetts. steven_dubois@dfci.harvard.edu.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print-Electronic", "pubTypeList": {"pubType": ["Clinical Trial, Phase II", "Research Support, Non-U.S. Gov't", "research-article", "Journal Article", "Research Support, N.I.H., Extramural"]}, "grantsList": {"grant": [{"grantId": "UL1 RR024131", "agency": "NCRR NIH HHS", "acronym": "RR", "orderIn": "0"}, {"grantId": "P30 CA015083", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}, {"grantId": "P01 CA081403", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}]}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Neuroblastoma", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DG", "qualifierName": "diagnostic imaging", "majorTopic_YN": "N"}, {"abbreviation": "DT", "qualifierName": "drug therapy", "majorTopic_YN": "Y"}, {"abbreviation": "MO", "qualifierName": "mortality", "majorTopic_YN": "N"}, {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Neoplasm Recurrence, Local"}, {"majorTopic_YN": "N", "descriptorName": "Azepines", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}, {"abbreviation": "PK", "qualifierName": "pharmacokinetics", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Pyrimidines", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}, {"abbreviation": "PK", "qualifierName": "pharmacokinetics", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Antineoplastic Combined Chemotherapy Protocols", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}, {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Tomography, X-Ray Computed"}, {"majorTopic_YN": "N", "descriptorName": "Magnetic Resonance Imaging"}, {"majorTopic_YN": "N", "descriptorName": "Drug Monitoring"}, {"majorTopic_YN": "N", "descriptorName": "Treatment Outcome"}, {"majorTopic_YN": "N", "descriptorName": "Retreatment"}, {"majorTopic_YN": "N", "descriptorName": "Cohort Studies"}, {"majorTopic_YN": "N", "descriptorName": "Drug Resistance, Neoplasm"}, {"majorTopic_YN": "N", "descriptorName": "Adolescent"}, {"majorTopic_YN": "N", "descriptorName": "Adult"}, {"majorTopic_YN": "N", "descriptorName": "Child"}, {"majorTopic_YN": "N", "descriptorName": "Child, Preschool"}, {"majorTopic_YN": "N", "descriptorName": "Infant"}, {"majorTopic_YN": "N", "descriptorName": "Female"}, {"majorTopic_YN": "N", "descriptorName": "Male"}, {"majorTopic_YN": "N", "descriptorName": "Young Adult"}, {"majorTopic_YN": "N", "descriptorName": "Irinotecan", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}, {"abbreviation": "PK", "qualifierName": "pharmacokinetics", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Temozolomide", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}, {"abbreviation": "PK", "qualifierName": "pharmacokinetics", "majorTopic_YN": "N"}]}}]}, "chemicalList": {"chemical": [{"name": "Pyrimidines", "registryNumber": "0"}, {"name": "Azepines", "registryNumber": "0"}, {"name": "MLN 8237", "registryNumber": "0"}, {"name": "irinotecan", "registryNumber": "7673326042"}, {"name": "temozolomide", "registryNumber": "YF1K15M17Y"}]}, "subsetList": {"subset": {"code": "IM", "name": "Index Medicus"}}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1158/1078-0432.CCR-18-1381"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6295246"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6295246?pdf=render"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1158/1078-0432.ccr-18-1381"}]}, "isOpenAccess": "N", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "Y", "citedByCount": "16", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "authMan": "Y", "epmcAuthMan": "N", "nihAuthMan": "Y", "manuscriptId": "NIHMS1503516", "hasTMAccessionNumbers": "Y", "tmAccessionTypeList": {"accessionType": ["refsnp", "nct"]}, "dateOfCompletion": "2019-12-18", "dateOfCreation": "2018-08-11", "firstIndexDate": "2018-08-10", "fullTextReceivedDate": "2020-10-22", "dateOfRevision": "2019-12-18", "electronicPublicationDate": "2018-08-09", "firstPublicationDate": "2018-08-09", "embargoDate": "2019-12-15"}, "abstract": "<h4>Purpose</h4>In phase I testing, alisertib tablets with irinotecan and temozolomide showed significant antitumor activity in patients with neuroblastoma. This study sought to confirm activity of this regimen; evaluate an alisertib oral solution; and evaluate biomarkers of clinical outcomes.<h4>Patients and methods</h4>We conducted a two-stage phase II trial of alisertib tablets (60 mg/m<sup>2</sup>/dose \u00d7 7 days), irinotecan (50 mg/m<sup>2</sup>/dose i.v. \u00d7 5 days), and temozolomide (100 mg/m<sup>2</sup>/dose orally \u00d7 5 days) in patients with relapsed or refractory neuroblastoma. The primary endpoint was best objective response. A separate cohort was treated with alisertib at 45 mg/m<sup>2</sup> using oral solution instead of tablets. Exploratory analyses sought to identify predictors of toxicity, response, and progression-free survival (PFS) using pooled data from phase I, phase II, and oral solution cohorts.<h4>Results</h4>Twenty and 12 eligible patients were treated in the phase II and oral solution cohorts, respectively. Hematologic toxicities were the most common adverse events. In phase II, partial responses were observed in 19 evaluable patients (21%). The estimated PFS at 1 year was 34%. In the oral solution cohort, 3 patients (25%) had first cycle dose-limiting toxicity (DLT). Alisertib oral solution at 45 mg/m<sup>2</sup> had significantly higher median <i>C</i> <sub>max</sub> and exposure compared with tablets at 60 mg/m<sup>2</sup>. Higher alisertib trough concentration was associated with first cycle DLT, whereas <i>MYCN</i> amplification was associated with inferior PFS.<h4>Conclusions</h4>This combination shows antitumor activity, particularly in patients with <i>MYCN</i> nonamplified tumors. Data on an alisertib oral solution expand the population able to be treated with this agent.", "journaltitle": "Clinical cancer research : an official journal of the American Association for Cancer Research", "authorinfo": ["DuBois SG", "Mosse YP", "Fox E", "Kudgus RA", "Reid JM", "McGovern R", "Groshen S", "Bagatell R", "Maris JM", "Twist CJ", "Goldsmith K", "Granger MM", "Weiss B", "Park JR", "Macy ME", "Cohn SL", "Yanik G", "Wagner LM", "Hawkins R", "Courtier J", "Lai H", "Goodarzian F", "Shimada H", "Boucher N", "Czarnecki S", "Luo C", "Tsao-Wei D", "Matthay KK", "Marachelian A"], "title": "Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma."}